Capabilities

Type Name/Description Filesize Download
application/pdf icon
Ocular Pharmacokinetics
Pharmacokinetics is generally defined as the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body over a period of time. In the case of ocular pharmacokinetics, all of the above activities occur but the site of action may be either the meibomian glands, cornea, aqueous humor, vitreous humor, retina, and/or choroid depending on the ocular disease targeted.
633 KB Ocular Pharmacokinetics
application/pdf icon
General Capabilities
PharmOptima's proven approach to drug discovery and optimization focuses on our ability to maximize your program's success by developing customized solutions for your intellectual property problems and providing the highest quality data in a rapid timeframe to move your compound up the value chain. Founded by scientists with broad expertise and years of pharmaceutical experience, we truly understand the value of solving the complex problems associated with drug development. Our multidisciplinary scientific team consults with you to provide research strategies to optimize your success.
581.61 KB General Capabilities
application/pdf icon
Biomarker and Assay Capabilities
PharmOptima provides custom assay development services to customers worldwide. PharmOptima scientists have extensive experience in multiple assay development platforms. Our staff will work with you to develop assays to meet your specific research needs.In many cases biomarkers are available from human, rat, mouse and non-human primate. We have the expertise and experience to clone and express proteins if what you need is not commercially available.
391.41 KB Biomarker and Assay Capabilities
application/pdf icon
Ocular Capabilities
PharmOptima's ophthalmic services begin, run and conclude with a high level of technical expertise. From specialized ocular dosing by trained scientists, to the precise dissection of specific ocular tissues by our specialists, followed by exacting sample processing and bioanalysis by PharmOptima's experienced staff; we stand out against the large CRO model of generalized necropsy technicians and crash & shoot discovery bioanalysis. PharmOptima's bioanalytical team has extensive experience processing, homogenizing and extracting ocular fluids and tissues. We have developed LC-MS/MS methods for hundreds of compounds.
439.6 KB Ocular Capabilities
application/pdf icon
14 Day Rat Nephrotoxicity Study with Kidney Injury Biomarkers
Biomarkers panel identified gentamicin, at the dose tested, as a nephrotoxin as early as only 3 days of administration. Traditional clinical markers of kidney toxicity, Serum Creatinine and BUN, would not have identified gentamicin, at the dose tested, as a nephrotoxin even after 14 days of administration. PharmOptima's ECL Biomarker Nephrotoxicity Testing is: - Cost effective method - Faster than traditional histopathology method - More sensitive than traditional clinical markers Call or email for more information or a quote
534.37 KB 14 Day Rat Nephrotoxicity Study with Kidney Injury Biomarkers
application/pdf icon
SMN in Whole Blood Assay
PharmOptima's proprietary SMN assay allows for the measurement of SMN protein in whole blood, requiring as little as 5μl whole blood. Statistically significant differences noted between Type 2 patients and carriers.
785.39 KB SMN in Whole Blood Assay
application/pdf icon
Survival Motor Neuron (SMN)-Electrochemiluminescence (ECL) Assay Development and Characteristics
PharmOptima has developed a sensitive electrochemiluminescence (ECL) based immunoassay for measuring SMN protein in as little as 5μL of whole blood. The assay has been used to accurately quantify SMN protein in whole blood, cerebral spinal fluid (CSF) and tissue homogenates including spinal cord and muscle. The SMN-ECL immunoassay enables accurate measurement of SMN in whole blood and other tissues. The assay has been qualified according to FDA guidelines and is being
785.39 KB SMN in Whole Blood Assay